Taltobulin
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Taltobulin
Description:
Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis[1].Product Name Alternative:
HTI-286; SPA-110UNSPSC:
12352203Hazard Statement:
H302, H315, H319, H335Target:
ADC Payload; Apoptosis; Microtubule/TubulinType:
ADC RelatedRelated Pathways:
Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; CytoskeletonApplications:
Cancer-programmed cell deathField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/taltobulin.htmlPurity:
99.90Solubility:
DMSO : ≥ 100 mg/mLSmiles:
CC(C)(C)[C@H](NC([C@H](C(C)(C1=CC=CC=C1)C)NC)=O)C(N([C@@H](C(C)C)/C=C(C(O)=O)\C)C)=OMolecular Formula:
C27H43N3O4Molecular Weight:
473.65Precautions:
H302, H315, H319, H335References & Citations:
[1]Loganzo F, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003 Apr 15;63 (8) :1838-45.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
ADC RelatedClinical Information:
Phase 1Isoform:
Traditional Cytotoxic AgentsCAS Number:
[228266-40-8]
